Biotechnology company developing therapies for pulmonary arterial hypertension and other diseases.
Liquidia Corporation is a dynamic biopharmaceutical firm dedicated to addressing critical unmet medical needs across the United States. Leveraging its robust capabilities in development, manufacturing, and commercialization, the company focuses on advancing innovative therapeutic solutions. Among its flagship product candidates is YUTREPIA, an inhaled dry powder formulation of treprostinil designed specifically for the treatment of pulmonary arterial hypertension, a debilitating condition affecting patients worldwide.
In addition to its groundbreaking advancements in pulmonary medicine, Liquidia Corporation plays a pivotal role in the distribution of generic treprostinil injection within the United States. This commitment underscores its mission to enhance accessibility to essential treatments while driving efficiencies in healthcare delivery. The company's comprehensive approach encompasses not only the development of novel therapies but also strategic partnerships and collaborations to broaden its impact and reach.
Founded in 2004 and headquartered in Morrisville, North Carolina, Liquidia Corporation continues to expand its footprint in the biopharmaceutical sector. Its state-of-the-art facilities and cutting-edge research capabilities position it as a leader in the development of differentiated therapies. With a strong commitment to innovation and patient care, Liquidia Corporation remains dedicated to improving the lives of individuals through transformative healthcare solutions.